|
1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar
|
|
2
|
Travis WD, Travis LB and Devesa SS: Lung
cancer. Cancer. 75(Suppl 1): 191–202. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Riely GJ, Kris MG, Rosenbaum D, et al:
Frequency and distinctive spectrum of KRAS mutations in never
smokers with lung adenocarcinoma. Clin Cancer Res. 14:5731–5734.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marks JL, Broderick S, Zhou Q, et al:
Prognostic and therapeutic implications of EGFR and KRAS mutations
in resected lung adenocarcinoma. J Thorac Oncol. 3:111–116. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kosaka T, Yatabe Y, Onozato R, Kuwano H
and Mitsudomi T: Prognostic implication of EGFR, KRAS, and TP53
gene mutations in a large cohort of Japanese patients with
surgically treated lung adenocarcinoma. J Thorac Oncol. 4:22–29.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gill RK, Yang SH, Meerzaman D, et al:
Frequent homozygous deletion of the LKB1/STK11 gene in non-small
cell lung cancer. Oncogene. 30:3784–3791. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ding L, Getz G, Wheeler DA, et al: Somatic
mutations affect key pathways in lung adenocarcinoma. Nature.
455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gao SP, Mark KG, Leslie K, et al:
Mutations in the EGFR kinase domain mediate STAT3 activation via
IL-6 production in human lung adenocarcinomas. J Clin Invest.
117:3846–3856. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hiramatsu M, Ninomiya H, Inamura K, et al:
Activation status of receptor tyrosine kinase downstream pathways
in primary lung adenocarcinoma with reference of KRAS and EGFR
mutations. Lung Cancer. 70:94–102. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stearman RS, Dwyer-Nield L, Zerbe L, et
al: Analysis of orthologous gene expression between human pulmonary
adenocarcinoma and a carcinogen-induced murine model. Am J Pathol.
167:1763–1775. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wachi S, Yoneda K and Wu R:
Interactome-transcriptome analysis reveals the high centrality of
genes differentially expressed in lung cancer tissues.
Bioinformatics. 21:4205–4208. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Smyth GK: Linear models and empirical
bayes methods for assessing differential expression in microarray
experiments. Stat Appl Genet Mol Biol. 3:Article 32004.
|
|
13
|
Irizarry RA, Hobbs B, Collin F, et al:
Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics. 4:249–264.
2003. View Article : Google Scholar
|
|
14
|
Wingender E: The TRANSFAC project as an
example of framework technology that supports the analysis of
genomic regulation. Brief Bioinform. 9:326–332. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang C, Xuan Z, Zhao F and Zhang MQ:
TRED: a transcriptional regulatory element database, new entries
and other development. Nucleic Acids Res. 35:D137–D140. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kanehisa M: The KEGG database (Review).
Novartis Found Symp. 247:91–101. 2002. View Article : Google Scholar
|
|
17
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009.PubMed/NCBI
|
|
18
|
Chang TH and Szabo E: Induction of
differentiation and apoptosis by ligands of peroxisome
proliferator-activated receptor γ in non-small cell lung cancer.
Cancer Res. 60:1129–1138. 2000.
|
|
19
|
Theocharis S, Kanelli H, Politi E, et al:
Expression of peroxisome proliferator activated receptor-gamma in
non-small cell lung carcinoma: correlation with histological type
and grade. Lung Cancer. 36:249–255. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Keshamouni VG, Reddy RC, Arenberg DA, et
al: Peroxisome proliferator-activated receptor-γ activation
inhibits tumor progression in non-small-cell lung cancer. Oncogene.
23:100–108. 2004.
|
|
21
|
Hall PA, Kearsey JM, Coates PJ, Norman DG,
Warbrick E and Cox LS: Characterisation of the interaction between
PCNA and Gadd45. Oncogene. 10:2427–2433. 1995.PubMed/NCBI
|
|
22
|
Zhan Q, Antinore MJ, Wang XW, et al:
Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase
activity by the p53-regulated protein Gadd45. Oncogene.
18:2892–2900. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bruemmer D, Yin F, Liu J, et al:
Regulation of the growth arrest and DNA damage-inducible gene 45
(GADD45) by peroxisome proliferator-activated receptor γ in
vascular smooth muscle cells. Circ Res. 93:e38–e47. 2003.
|
|
24
|
Na YK, Lee SM, Hong HS, Kim JB, Park JY
and Kim DS: Hypermethylation of growth arrest DNA-damage-inducible
gene 45 in non-small cell lung cancer and its relationship with
clinicopathologic features. Mol Cells. 30:89–92. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schoonjans K, Peinado-Onsurbe J, Lefebvre
AM, et al: PPARalpha and PPARgamma activators direct a distinct
tissue-specific transcriptional response via a PPRE in the
lipoprotein lipase gene. EMBO J. 15:5336–5348. 1996.PubMed/NCBI
|
|
26
|
Li L, Beauchamp MC and Renier G:
Peroxisome proliferator-activated receptor alpha and gamma agonists
upregulate human macrophage lipoprotein lipase expression.
Atherosclerosis. 165:101–110. 2002. View Article : Google Scholar
|
|
27
|
Kuemmerle NB, Rysman E, Lombardo PS, et
al: Lipoprotein lipase links dietary fat to solid tumor cell
proliferation. Mol Cancer Ther. 10:427–436. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cerne D, Zitnik IP and Sok M: Increased
fatty acid synthase activity in non-small cell lung cancer tissue
is a weaker predictor of shorter patient survival than increased
lipoprotein lipase activity. Arch Med Res. 41:405–409. 2010.
View Article : Google Scholar
|
|
29
|
Shindoh M, Higashino F and Kohgo T: E1AF,
an ets-oncogene family transcription factor (Review). Cancer Lett.
216:1–8. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hiroumi H, Dosaka-Akita H, Yoshida K, et
al: Expression of E1AF/PEA3, an Ets-related transcription factor in
human non-small-cell lung cancers: Its relevance in cell motility
and invasion. Int J Cancer. 93:786–791. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Higashino F, Yoshida K, Noumi T, Seiki M
and Fujinaga K: Ets-related protein E1A-F can activate three
different matrix metalloproteinase gene promoters. Oncogene.
10:1461–1463. 1995.PubMed/NCBI
|
|
32
|
Keld R, Guo B, Downey P, Gulmann C, Ang YS
and Sharrocks AD: The ERK MAP kinase-PEA3/ETV4-MMP-1 axis is
operative in oesophageal adenocarcinoma. Mol Cancer. 9:3132010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Truong A and Ben-David Y: The role of
Fli-1 in normal cell function and malignant transformation
(Review). Oncogene. 19:6482–6489. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
May WA, Arvand A, Thompson AD, Braun BS,
Wright M and Denny CT: EWS/FLI1-induced manic fringe renders NIH
3T3 cells tumorigenic. Nat Genet. 17:495–497. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Thompson AD, Teitell MA, Arvand A and
Denny CT: Divergent Ewing’s sarcoma EWS/ETS fusions confer a common
tumorigenic phenotype on NIH3T3 cells. Oncogene. 18:5506–5513.
1999.
|
|
36
|
Im YH, Kim HT, Lee C, et al: EWS-FLI1,
EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all
suppress transcription of transforming growth factor β type II
receptor gene. Cancer Res. 60:1536–1540. 2000.PubMed/NCBI
|
|
37
|
Hahm KB, Cho K, Lee C, et al: Repression
of the gene encoding the TGF-β type II receptor is a major target
of the EWS-FLI1 oncoprotein. Nat Genet. 23:222–227. 1999.
|
|
38
|
Rossi S, Orvieto E, Furlanetto A, Laurino
L, Ninfo V and Dei Tos AP: Utility of the immunohistochemical
detection of FLI-1 expression in round cell and vascular neoplasm
using a monoclonal antibody. Mod Pathol. 17:547–552. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pereira R, Quang CT, Lesault I, Dolznig H,
Beug H and Ghysdael J: FLI-1 inhibits differentiation and induces
proliferation of primary erythroblasts. Oncogene. 18:1597–1608.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Grumont RJ, Fecondo J and Gerondakis S:
Alternate RNA splicing of murine nfkb1 generates a nuclear isoform
of the p50 precursor NF-kappa B1 that can function as a
transactivator of NF-kappa B-regulated transcription. Mol Cell
Biol. 14:8460–8470. 1994.PubMed/NCBI
|
|
41
|
Wharry CE, Haines KM, Carroll RG and May
MJ: Constitutive non-canonical NFkappaB signaling in pancreatic
cancer cells. Cancer Biol Ther. 8:1567–1576. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hiscott J, Marois J, Garoufalis J, et al:
Characterization of a functional NF-kappa B site in the human
interleukin 1 beta promoter: evidence for a positive autoregulatory
loop. Mol Cell Biol. 13:6231–6240. 1993.PubMed/NCBI
|
|
43
|
Zienolddiny S, Ryberg D, Maggini V, Skaug
V, Canzian F and Haugen A: Polymorphisms of the interleukin-1 β
gene are associated with increased risk of non-small cell lung
cancer. Int J Cancer. 109:353–356. 2004.
|
|
44
|
Hu HM, Tian Q, Baer M, et al: The C/EBP
bZIP domain can mediate lipopolysaccharide induction of the
proinflammatory cytokines interleukin-6 and monocyte
chemoattractant protein-1. J Biol Chem. 275:16373–16381. 2000.
View Article : Google Scholar
|
|
45
|
Yamaji H, Iizasa T, Koh E, et al:
Correlation between interleukin 6 production and tumor
proliferation in non-small cell lung cancer. Cancer Immunol
Immunother. 53:786–792. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xiao W, Hodge DR, Wang L, Yang X, Zhang X
and Farrar WL: Co-operative functions between nuclear factors
NFkappaB and CCAT/enhancer-binding protein-beta (C/EBP-beta)
regulate the IL-6 promoter in autocrine human prostate cancer
cells. Prostate. 61:354–370. 2004. View Article : Google Scholar
|
|
47
|
Tang T, Shi Y, Opalenik SR, et al:
Expression of the TAL1/SCL transcription factor in physiological
and pathological vascular processes. J Pathol. 210:121–129. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Erez A, Perelman M, Hewitt SM, et al: Sil
overexpression in lung cancer characterizes tumors with increased
mitotic activity. Oncogene. 23:5371–5377. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Glubb DM, Cerri E, Giese A, et al: Novel
functional germline variants in the vascular endothelial growth
factor receptor 2 gene (KDR) and their effect on gene expression
and micro-vessel density in lung cancer. Clin Cancer Res.
17:5257–5267. 2011. View Article : Google Scholar
|
|
50
|
Sanmartin E, Jantus Lewintre E, Sirera R,
et al: Soluble vascular endothelial growth factor receptor 2
(VEGFR2): New biomarker in advanced non-small cell lung cancer
(NSCLC)? J Clin Oncol (Suppl). 27:e221082009.
|
|
51
|
Tanaka A, Itoh F, Nishiyama K, et al:
Inhibition of endothelial cell activation by bHLH protein E2–2 and
its impairment of angiogenesis. Blood. 115:4138–4147. 2010.
|
|
52
|
Tanaka A, Itoh F, Itoh S and Kato M:
TAL1/SCL relieves the E2-2-mediated repression of VEGFR2 promoter
activity. J Biochem. 145:129–135. 2009. View Article : Google Scholar : PubMed/NCBI
|
